How does growth hormone affect insulin action and glucose metabolism?

Growth Hormone's Antagonistic Effects on Insulin Action

Growth hormone fundamentally opposes insulin's effects on glucose metabolism by inducing insulin resistance through both hepatic and peripheral mechanisms, primarily mediated by increased lipolysis and free fatty acid flux. 1, 2

Primary Metabolic Antagonism

Growth hormone acts as a counterregulatory hormone that directly antagonizes insulin's actions on glucose metabolism through multiple pathways 1:

• GH increases lipolysis and free fatty acid (FFA) release, which is its most prominent metabolic effect and the primary mechanism driving insulin resistance 1, 2
• Elevated FFAs cause lipotoxicity in liver and skeletal muscle, suppressing insulin's ability to suppress hepatic glucose production and stimulate peripheral glucose uptake 2
• GH decreases glucose oxidation by redirecting metabolism toward lipid oxidation, effectively competing with insulin's glucose-lowering actions 3

Dual Effects on Insulin Sensitivity

The relationship between GH and insulin demonstrates a dose-dependent and time-dependent pattern 4, 5:

Physiologic GH Levels

• At physiologic concentrations, GH causes a rightward shift in insulin dose-response curves for both hepatic glucose suppression (half-maximal response at 37 vs 20 μU/mL) and peripheral glucose utilization (half-maximal response at 98 vs 52 μU/mL) 4
• This represents a post-receptor defect in insulin action, as monocyte insulin receptor binding remains unchanged 4
• GH redistributes glucose flux away from oxidation toward non-oxidative pathways like glycogen synthesis, particularly important during fasting states 3

Pathologic GH Excess

• In acromegaly or high-dose GH therapy, frank diabetes can develop with increased hepatic glucose production, decreased muscle glucose uptake, and rising blood glucose 3
• Patients with intact beta-cell function compensate with hyperinsulinemia, which may increase long-term cardiovascular risk 3

Clinical Implications During GH Therapy

Metabolic Monitoring Requirements

The American Academy of Pediatrics mandates specific glucose surveillance during GH treatment 6, 7:

• Monitor serum glucose at every 3-6 month clinic visit to detect glucose metabolism alterations 6, 7
• Increased insulin secretion and hyperinsulinemia may occur, particularly in patients with obesity or diabetes risk factors, requiring close monitoring 6, 7
• GH therapy is absolutely contraindicated in uncontrolled diabetes mellitus 8

Paradoxical Effects in GH Deficiency

• GH-deficient patients are paradoxically insulin resistant due to increased adiposity and reduced lean body mass, which temporarily worsens when GH treatment is initiated 1
• Low-dose GH replacement (0.3 mg/day) can improve insulin sensitivity long-term by increasing the M value from 13.8 to 23.7 μmol/kg/min after 48 weeks, with improved disposition index indicating better whole-body glucose metabolism 9

Pediatric Considerations

• In children with GH deficiency, long-term treatment increases fasting insulin and insulin during OGTT, while fasting glucose rises but OGTT glucose remains stable 10
• Changes correlate with IGF-1 increases and GH doses, with higher IGF-1 SDS predicting greater metabolic changes 10
• All cases of impaired fasting glucose or impaired glucose tolerance detected during GH treatment are reversible with dietary intervention and do not progress to diabetes 10

Mechanistic Pathways

GH antagonizes insulin through shared intracellular signaling pathways 5:

• GH and insulin both utilize JAK2/STAT, MAPK, and IRS/PI3K/Akt pathways, creating molecular crosstalk where insulin can attenuate GH signaling 5
• The effect depends critically on insulin dose and duration, with higher doses and longer exposure increasing GH signal suppression 5
• SOCS proteins and JAK2-IRS interactions mediate the competitive inhibition between these hormones 5

Drug Interactions

The FDA notes that somatropin (GH) may reduce the blood-glucose-lowering effect of insulin, requiring dose adjustments 11:

• Corticosteroids, thyroid hormones, and GH are listed together as substances that antagonize insulin action 11
• Insulin requirements may need adjustment in patients receiving GH therapy 11

Clinical Pitfalls to Avoid

• Do not rely on HbA1c alone for monitoring during GH therapy, as it may remain normal even with impaired fasting glucose or glucose tolerance 10
• Recognize that initial worsening of insulin sensitivity when starting GH in deficient patients is expected and typically improves with continued low-dose therapy 9, 1
• Avoid high-dose GH regimens that push IGF-1 above the normal range, as this increases risk of persistent hyperinsulinemia and glucose intolerance 9